BerGenBio, a Bergen, Norway-based biopharmaceutical research and development company, has raised NOK7m in funding from Sarsia Seed and Development funds.
The company intends to use the capital to continue its research and development activities into new and original cancer treatments.
BerGenBio is based on proprietary platform technology called CellSelect™, which uses information from RNAi screening studies to identify novel drug targets involved in disease. the company has a deep understanding of Cancer biology and in particular the tumor micro-environment, EMT and mechanisms of drug resistance.
Led by CEO Richard Godfrey, BerGenBio has also been awarded grants from Innovation Norway and FORNY and has received additional financial support from the NFR to enable its life sciences graduate recruits to continue PhD studies.